

# Maria Frantzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7379364/publications.pdf>

Version: 2024-02-01

38  
papers

1,119  
citations

394421

19  
h-index

414414

32  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1900  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. <i>Clinical and Translational Medicine</i> , 2014, 3, 7.	4.0	105
2	Profilin 1 is a Potential Biomarker for Bladder Cancer Aggressiveness. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.009449.	3.8	97
3	Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. <i>Clinical Cancer Research</i> , 2016, 22, 4077-4086.	7.0	90
4	Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future. <i>Electrophoresis</i> , 2019, 40, 2294-2308.	2.4	89
5	Developing proteomic biomarkers for bladder cancer: towards clinical application. <i>Nature Reviews Urology</i> , 2015, 12, 317-330.	3.8	69
6	Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. <i>Journal of Proteomics</i> , 2014, 98, 44-58.	2.4	64
7	Proteomics and Metabolomics for AKI Diagnosis. <i>Seminars in Nephrology</i> , 2018, 38, 63-87.	1.6	59
8	Proteomics biomarkers for solid tumors: Current status and future prospects. <i>Mass Spectrometry Reviews</i> , 2019, 38, 49-78.	5.4	53
9	Proteomics in Drug Development: The Dawn of a New Era?. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800087.	1.6	48
10	Proteome-based classification of Nonmuscle Invasive Bladder Cancer. <i>International Journal of Cancer</i> , 2020, 146, 281-294.	5.1	35
11	Biomarkers for bladder cancer aggressiveness. <i>Current Opinion in Urology</i> , 2012, 22, 390-396.	1.8	32
12	Urinary CE-MS peptide marker pattern for detection of solid tumors. <i>Scientific Reports</i> , 2018, 8, 5227.	3.3	28
13	Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. <i>Oncotarget</i> , 2017, 8, 69435-69455.	1.8	27
14	Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on bladder cancer. <i>Proteomics - Clinical Applications</i> , 2013, 7, 779-793.	1.6	26
15	CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. <i>British Journal of Cancer</i> , 2019, 120, 1120-1128.	6.4	25
16	Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions. <i>Bladder Cancer</i> , 2017, 3, 1-18.	0.4	24
17	Clinical Proteomics: Closing the Gap from Discovery to Implementation. <i>Proteomics</i> , 2018, 18, e1700463.	2.2	24
18	Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700074.	1.6	21

#	ARTICLE	IF	CITATIONS
19	IMAC Fractionation in Combination with LC-MS Reveals H2B and NIF-1 Peptides As Potential Bladder Cancer Biomarkers. <i>Journal of Proteome Research</i> , 2013, 12, 3969-3979.	3.7	20
20	Drug repurposing in oncology. <i>Lancet Oncology</i> , The, 2020, 21, e543.	10.7	20
21	Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma. <i>Journal of Biomedical Science</i> , 2020, 27, 13.	7.0	19
22	Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca <sup>2+</sup> signaling in T24M-based bladder cancer models. <i>Oncotarget</i> , 2016, 7, 70750-70768.	1.8	19
23	Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800111.	1.6	17
24	Recent progress in urinary proteome analysis for prostate cancer diagnosis and management. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1539-1554.	3.1	13
25	Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of omics findings. <i>Scientific Reports</i> , 2016, 6, 25619.	3.3	12
26	Urinary peptide panel for prognostic assessment of bladder cancer relapse. <i>Scientific Reports</i> , 2019, 9, 7635.	3.3	12
27	A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures. <i>Cancers</i> , 2020, 12, 3519.	3.7	12
28	Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation. <i>Diagnostics</i> , 2020, 10, 655.	2.6	12
29	Promise and Implementation of Proteomic Prostate Cancer Biomarkers. <i>Diagnostics</i> , 2018, 8, 57.	2.6	9
30	Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 658.	2.6	7
31	Pathophysiological Implications of Urinary Peptides in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3786.	3.7	7
32	A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data. <i>Cancers</i> , 2022, 14, 1995.	3.7	5
33	Urinary proteomic biomarkers in oncology: ready for implementation?. <i>Expert Review of Proteomics</i> , 2019, 16, 49-63.	3.0	4
34	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 383-400.	0.7	4
35	Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 2195-2203.	2.2	4
36	Clinical Proteomics on the Path Toward Implementation: First Promises Delivered. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800094.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature. <i>Cancers</i> , 2022, 14, 2542.	3.7	3
38	Targeting the Proteome of Cellular Fractions: Focus on Secreted Proteins. <i>Methods in Molecular Biology</i> , 2015, 1243, 29-41.	0.9	1